Abstract
Phosphoprotein driven cellular signaling events represent most of the new molecular targets for cancer treatment. Application of reverse-phase protein microarray technology for the study of ongoing signaling activity within breast tumor specimens holds great potential for elucidating and profiling signaling activity in real-time for patient-tailored therapy. Analysis of laser capture microdissection primary human breast tumors and metastatic lesions reveals pathway specific profiles and a new way to classify cancer based on functional signaling portraits. Moreover, the data demonstrate the requirement of laser capture microdissection for analysis and reveal the metastasis-specific changes that occur within a new microenvironment. Analysis of biopsy material from clinical trials for targeted therapeutics demonstrates the feasibility and utility of comprehensive signal pathway activation profiling for molecular analysis.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Breast Neoplasms / drug therapy
-
Breast Neoplasms / metabolism*
-
Breast Neoplasms / pathology
-
Cluster Analysis
-
Erlotinib Hydrochloride
-
Female
-
Humans
-
Intracellular Signaling Peptides and Proteins / metabolism*
-
Lasers
-
Liver Neoplasms / drug therapy
-
Liver Neoplasms / metabolism
-
Liver Neoplasms / secondary
-
Microdissection / methods
-
Phosphoproteins / metabolism
-
Phosphorylation
-
Protein Kinase Inhibitors / therapeutic use
-
Protein Kinases / metabolism
-
Proteomics / methods*
-
Proto-Oncogene Proteins c-akt / metabolism
-
Quinazolines / therapeutic use
-
Receptor Protein-Tyrosine Kinases / metabolism
-
Signal Transduction*
Substances
-
Intracellular Signaling Peptides and Proteins
-
Phosphoproteins
-
Protein Kinase Inhibitors
-
Quinazolines
-
Erlotinib Hydrochloride
-
Protein Kinases
-
Receptor Protein-Tyrosine Kinases
-
Proto-Oncogene Proteins c-akt